Iovance Biotherapeutics I...

NASDAQ: IOVA · Real-Time Price · USD
1.84
0.02 (1.10%)
At close: Jun 04, 2025, 3:59 PM
1.83
-0.53%
After-hours: Jun 04, 2025, 07:58 PM EDT

Iovance Biotherapeutics Statistics

Share Statistics

Iovance Biotherapeutics has 333.93M shares outstanding. The number of shares has increased by 17.17% in one year.

Shares Outstanding 333.93M
Shares Change (YoY) 17.17%
Shares Change (QoQ) 7.58%
Owned by Institutions (%) 79.63%
Shares Floating n/a
Failed to Deliver (FTD) Shares 101,116
FTD / Avg. Volume 0.8%

Short Selling Information

The latest short interest is 77.02M, so 23.06% of the outstanding shares have been sold short.

Short Interest 77.02M
Short % of Shares Out 23.06%
Short % of Float 25.26%
Short Ratio (days to cover) 3.03

Valuation Ratios

The PE ratio is -5.76 and the forward PE ratio is -2.48. Iovance Biotherapeutics's PEG ratio is 0.18.

PE Ratio -5.76
Forward PE -2.48
PS Ratio 13.07
Forward PS 0.5
PB Ratio 3.02
P/FCF Ratio -5.89
PEG Ratio 0.18
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Iovance Biotherapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.74, with a Debt / Equity ratio of 0.08.

Current Ratio 3.74
Quick Ratio 3.31
Debt / Equity 0.08
Debt / EBITDA -0.17
Debt / FCF -0.16
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $195,787.59
Profits Per Employee $-444,125.3
Employee Count 838
Asset Turnover 0.18
Inventory Turnover 2.41

Taxes

Income Tax -2.83M
Effective Tax Rate 0.75%

Stock Price Statistics

The stock price has increased by -77.65% in the last 52 weeks. The beta is 1.06, so Iovance Biotherapeutics's price volatility has been higher than the market average.

Beta 1.06
52-Week Price Change -77.65%
50-Day Moving Average 2.79
200-Day Moving Average 6.78
Relative Strength Index (RSI) 36.31
Average Volume (20 Days) 12,691,504

Income Statement

In the last 12 months, Iovance Biotherapeutics had revenue of 164.07M and earned -372.18M in profits. Earnings per share was -1.28.

Revenue 164.07M
Gross Profit 40.08M
Operating Income -395.28M
Net Income -372.18M
EBITDA -351.67M
EBIT -395.28M
Earnings Per Share (EPS) -1.28
Full Income Statement

Balance Sheet

The company has 115.69M in cash and 58.26M in debt, giving a net cash position of 57.43M.

Cash & Cash Equivalents 115.69M
Total Debt 58.26M
Net Cash 57.43M
Retained Earnings -2.38B
Total Assets 966.74M
Working Capital 389.96M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -352.98M and capital expenditures -11.07M, giving a free cash flow of -364.05M.

Operating Cash Flow -352.98M
Capital Expenditures -11.07M
Free Cash Flow -364.05M
FCF Per Share -1.26
Full Cash Flow Statement

Margins

Gross margin is 24.43%, with operating and profit margins of -240.92% and -226.84%.

Gross Margin 24.43%
Operating Margin -240.92%
Pretax Margin -228.56%
Profit Margin -226.84%
EBITDA Margin -214.34%
EBIT Margin -240.92%
FCF Margin -221.88%

Dividends & Yields

IOVA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for IOVA is $10, which is 452.5% higher than the current price. The consensus rating is "Buy".

Price Target $10
Price Target Difference 452.5%
Analyst Consensus Buy
Analyst Count 10
Stock Forecasts

Stock Splits

The last stock split was on Sep 26, 2013. It was a backward split with a ratio of 1:100.

Last Split Date Sep 26, 2013
Split Type backward
Split Ratio 1:100

Scores

Altman Z-Score -2.45
Piotroski F-Score 4